The author concludes that “careful use of T3  and L-T4  can be critical mood-stabilizingoptions, especially for depressive illness that has not responded to first-line therapies,and can provide an alternative to other augmentation strategies such as atypicalantipsychotics, lithium, or esketamine/ketamine.”

This study enrolled individuals with AD who had been on a stable dose of donezepil forat least 90 days. They were then treated for 12 weeks with the addition of themodulator of cholinergic neurotransmission AD101, or placebo. Those receiving AD101had mean improvement of approximately 2 points on the Alzheimer DiseaseAssessment Scale-Cognitive (ADAS-Cog) Subscale. Individuals who had continued donezepil plusplacebo showed declines on ADAS-Cog.

The results of this study provide evidence that genetically predicted global cortical thickness (GCT) wasassociated with alcoholic drinks consumed per week and binge drinking frequency afteraccounting for neuropsychiatric phenotypes, substance use, trauma, andneurodegeneration.

In this study enrolling 478 young adults, of which 265 self-reported anxiety and 146 self-reported depression, high-dose vitamin B6 supplementation raised brain GABA levelsand reduced self-reported anxiety.

Panelists conclude that sNfL can be used as a biomarker to assess response totreatment in future trials. In the clinic setting, it could become valuable in directingtherapy; for example, in cases in which the patient is absent clinical signs of aggressiveMS and it’s unclear if they will benefit from infused, injected, or oral disease-modifyingtherapy.

Treatment resistance affects nearly half of all young people experiencing moderate-to-severe anxiety. In this 12-week open-label trial, patients received add-on CBD after noclinical improvement on therapy with CBT and/or antidepressant medication. There wasa more than 40% reduction in mean OASIS scores and no serious or unexpectedadverse events.